Literature DB >> 4004819

Myoadenylate deaminase deficiency: inherited and acquired forms.

W N Fishbein.   

Abstract

Myoadenylate deaminase deficiency, the most common of the known enzyme deficits of muscle, appears to occur in two forms. The primary type seems to be inherited as a complete gene block in an autosomal recessive pattern. Although occasionally diagnosed in infancy, when muscle biopsy is performed on a hypotonic but normoreflexic child, the deficiency is usually not symptomatic until adult or middle age, when muscle cramping and exercise intolerance develop. The skeletal muscle isozyme is immunologically, and presumably genetically, unique, and these patients have normal levels of adenylate deaminase in their other cells and tissues. A presumptive diagnosis can usually be made by an ischemic forearm exercise test, which shows a negligible increase in blood ammonia, despite a normal rise in lactate. Despite the absence of more than 99% of normal adenylate deaminase activity, the muscle biopsy shows no anatomic pathology, and other enzymes are at normal levels. These patients do not suffer progressive disease, and should be reassured, and encouraged to maintain physical activity. The heterozygous state is probably asymptomatic, except, perhaps, on extreme exercise, but may be associated with an increased incidence of malignant hyperthermia susceptibility. Since the gene defect is not rare, it is not surprising that some cases of the deficiency will be coincidentally associated with other neuromuscular disease. However, there is also a secondary form of myoadenylate deaminase deficiency, consequent to muscle damage from other disease. In this form, the residual activity is higher (1-10% of normal), may present rare foci of positive stain in the section, and reacts normally with antibody to the muscle isozyme. Other muscle enzymes are also depleted, although not as severely, and the prognosis in such cases is dictated by the primary disease. Since the heterozygous state is common, these patients might have been carriers, whose adenylate deaminase levels have been lowered for the deficient category by the advent of other neuromuscular disease.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 4004819     DOI: 10.1016/0006-2944(85)90024-9

Source DB:  PubMed          Journal:  Biochem Med        ISSN: 0006-2944


  20 in total

1.  Developmental forms of human skeletal-muscle AMP deaminase. The kinetic and regulatory properties of the enzyme.

Authors:  K Kaletha; G Nowak
Journal:  Biochem J       Date:  1988-01-01       Impact factor: 3.857

2.  The molecular basis of skeletal muscle weakness in a mouse model of inflammatory myopathy.

Authors:  William Coley; Sree Rayavarapu; Gouri S Pandey; Richard L Sabina; Jack H Van der Meulen; Beryl Ampong; Robert L Wortmann; Rashmi Rawat; Kanneboyina Nagaraju
Journal:  Arthritis Rheum       Date:  2012-11

3.  Evidence for sequential expression of multiple AMP deaminase isoforms during skeletal muscle development.

Authors:  R Marquetant; N M Desai; R L Sabina; E W Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  1987-04       Impact factor: 11.205

4.  Immunohistochemical analysis of human skeletal muscle AMP deaminase deficiency. Evidence of a correlation between the muscle HPRG content and the level of the residual AMP deaminase activity.

Authors:  Antonietta R M Sabbatini; Antonio Toscano; Mohammed Aguennouz; Daniela Martini; Enza Polizzi; Maria Ranieri-Raggi; Arthur J G Moir; Alba Migliorato; Olimpia Musumeci; Giuseppe Vita; Antonio Raggi
Journal:  J Muscle Res Cell Motil       Date:  2006-03-29       Impact factor: 2.698

Review 5.  Muscle biopsy evaluation in neuromuscular disorders.

Authors:  Nanette C Joyce; Björn Oskarsson; Lee-Way Jin
Journal:  Phys Med Rehabil Clin N Am       Date:  2012-08       Impact factor: 1.784

Review 6.  Myoadenylate deaminase deficiency.

Authors:  H H Goebel; A Bardosi
Journal:  Klin Wochenschr       Date:  1987-11-02

7.  Molecular basis of AMP deaminase deficiency in skeletal muscle.

Authors:  T Morisaki; M Gross; H Morisaki; D Pongratz; N Zöllner; E W Holmes
Journal:  Proc Natl Acad Sci U S A       Date:  1992-07-15       Impact factor: 11.205

Review 8.  Metabolic myopathies: functional evaluation by different exercise testing approaches.

Authors:  L Volpi; G Ricci; D Orsucci; R Alessi; F Bertolucci; S Piazza; C Simoncini; M Mancuso; G Siciliano
Journal:  Musculoskelet Surg       Date:  2011-03-04

9.  Comparative enzymology of AMP deaminase, adenylate kinase, and creatine kinase in vertebrate heart and skeletal muscle: the characteristic AMP deaminase levels of skeletal versus cardiac muscle are reversed in the North American toad.

Authors:  W N Fishbein; J I Davis; J W Foellmer
Journal:  J Comp Physiol B       Date:  1993       Impact factor: 2.200

10.  Developmental forms of human skeletal muscle AMP-deaminase.

Authors:  K Kaletha; J Spychala; G Nowak
Journal:  Experientia       Date:  1987-04-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.